Trials evaluating a glucagon-like peptide 1 (GLP-1) analogue have shown improved cardiovascular outcomes in patients with obesity without diabetes as well as with type 2 diabetes who were at high risk for cardiovascular events [[10], [11], [12]]. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.